Section Image

Pub Talk

"Revolutionizing Late Stage Clinical Trials:  
The 1747, Inc. Direct-To-Participant Method"

THURSDAY, MAY 23, 2002

By Dr. Naomi Fried
General Manager and Vice President of Business Development
1747, Inc.

Open to the Public. No fee. 5:00 - 7:00 p.m.
The Pub Talk begins at 6:00 p.m.

At this Pub, come hear how 1747 has developed an online system that dramatically reduces recruitment time, clinical trial duration, and direct trial costs, which means getting drugs to market faster.

The U.S. Food and Drug Administration (FDA) requires that the safety and efficacy of new drugs be demonstrated in randomized clinical trials before they can be marketed.  Traditionally, a pharmaceutical company contracts with a contract research organization (CRO) to coordinate the complex process of conducting a clinical trial.  The CRO recruits, identifies, and enrolls principal investigators (PIs) and clinical trial sites which, distribute the drugs, monitor their effects, and collect data from the participants.  This conventional method of setting up and conducting clinical trials at physical trial centers can take years and cost millions of dollars per year.  For a typical drug, every additional day it stays under patent protection can result in an additional $1-2 million of lost revenue.

Naomi Fried is General Manager and Vice President for Business Development at 1747, Inc.  Dr. Fried has over 12 years of experience in engineering and healthcare.  During the past four years, she has assisted eHealth start-ups in fundraising, developing business strategies and strategic partnerships, and creating Web-based revenue models.  Former clients have included medical content Web sites, vertical health portals, alternative health networks, and risk and disease management providers.  Dr. Fried advised Stanford’s School of Medicine in the creation and spin-out of its medical informatics Internet start-up e-SKOLAR (formerly SHINE), as well as served as Interim President during its first year.  Dr. Fried earned a B.S. in Chemistry from the University of California at Berkeley (summa cum laude) and a Ph.D. in Materials Science Engineering from MIT.

ABOUT 1747, INC.
1747, Inc. ( was founded by a team of healthcare and research professionals with many years of expertise in conducting clinical trials.  e.Lilly has invested in 1747, Inc. and Eli Lilly is 1747's first customer.  1747 has developed a proprietary, patent-pending online system that will eliminate the need for intermediaries such as CROs, clinical sites, and numerous PIs to conduct Phase III and Phase IV clinical trials.  1747's Direct-to-Participant (D2P) system verifies participants' eligibility, collects their informed consent, and then enrolls them using the Internet.  Participants are randomized online and study treatments are delivered directly to their homes.  Data is collected directly from the participant without the need for them to physically go to a trial center.  Using a virtual trial center rather than a "brick and mortar" one allows 1747, Inc. to conduct clinical trials more quickly and at significantly reduced cost.  Using the 1747 method, clinical trials that would take 3 years and cost $5mm using conventional trial centers can be completed in less than a year and at a fraction of the cost.  For example, a clinical trial (KALM trial) conducted using Version 1.0 of the 1747 system resulted in savings of approximately 85% in recruitment time, 65-75% in total trial duration, and nearly 80% in direct trial costs.

Dr. Naomi Fried
General Manager & Vice President of Business Development
1747, Inc.
T:  510.530.0796